[
  {
    "ts": null,
    "headline": "3 Potential Mid-Cap Biotech Buyout Targets In 2026",
    "summary": "Read about the 3 potential midcap biotech stocks primed for acquisition in 2026 amid rising M&A activity.",
    "url": "https://finnhub.io/api/news?id=b80d4fcf43cf5eb72305a5e2e1136fb788574bf0ee61d19151f95b9916aa996f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764786177,
      "headline": "3 Potential Mid-Cap Biotech Buyout Targets In 2026",
      "id": 137674630,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190546601/image_2190546601.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Read about the 3 potential midcap biotech stocks primed for acquisition in 2026 amid rising M&A activity.",
      "url": "https://finnhub.io/api/news?id=b80d4fcf43cf5eb72305a5e2e1136fb788574bf0ee61d19151f95b9916aa996f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript",
    "summary": "Amgen Inc. (AMGN) Citi Annual Global Healthcare Conference 2025 December 3, 2025 1:45 PM ESTCompany ParticipantsPeter Griffith - Executive VP & CFOKave...",
    "url": "https://finnhub.io/api/news?id=294815d954712108ccdbf1c531d7acd5ecbae7451413335f05bc813869c1b268",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764782609,
      "headline": "Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript",
      "id": 137674452,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen Inc. (AMGN) Citi Annual Global Healthcare Conference 2025 December 3, 2025 1:45 PM ESTCompany ParticipantsPeter Griffith - Executive VP & CFOKave...",
      "url": "https://finnhub.io/api/news?id=294815d954712108ccdbf1c531d7acd5ecbae7451413335f05bc813869c1b268"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript",
    "summary": "Amgen Inc. (AMGN) Evercore 8th Annual Healthcare Conference December 3, 2025 10:00 AM ESTCompany ParticipantsPeter Griffith - Executive VP & CFOKave...",
    "url": "https://finnhub.io/api/news?id=8781bc7327f29135c2e2dbe38799ab3764a2a2164c3b6d2ef6b187ad69ed6863",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764782007,
      "headline": "Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript",
      "id": 137674419,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen Inc. (AMGN) Evercore 8th Annual Healthcare Conference December 3, 2025 10:00 AM ESTCompany ParticipantsPeter Griffith - Executive VP & CFOKave...",
      "url": "https://finnhub.io/api/news?id=8781bc7327f29135c2e2dbe38799ab3764a2a2164c3b6d2ef6b187ad69ed6863"
    }
  },
  {
    "ts": null,
    "headline": "Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?",
    "summary": "Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.",
    "url": "https://finnhub.io/api/news?id=7f3a74107aeafcaabdcacaa5cd253e51b2ff148f09a335477dc214936b52ae82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764771960,
      "headline": "Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?",
      "id": 137672736,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.",
      "url": "https://finnhub.io/api/news?id=7f3a74107aeafcaabdcacaa5cd253e51b2ff148f09a335477dc214936b52ae82"
    }
  },
  {
    "ts": null,
    "headline": "Buy Verizon, December's Ideal \"Safer\" Dog Of The Dow",
    "summary": "Read the latest Dogs of the Dow update: see which top dividend stocks offer optimal value, growth forecasts, and safe yields.",
    "url": "https://finnhub.io/api/news?id=2667faafae3ff28b914df962f1f36c6af7bda25b202492689598e8cf884cc067",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764763343,
      "headline": "Buy Verizon, December's Ideal \"Safer\" Dog Of The Dow",
      "id": 137672165,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219303612/image_1219303612.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Read the latest Dogs of the Dow update: see which top dividend stocks offer optimal value, growth forecasts, and safe yields.",
      "url": "https://finnhub.io/api/news?id=2667faafae3ff28b914df962f1f36c6af7bda25b202492689598e8cf884cc067"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 270-point rally highlighted by gains in UnitedHealth, Nike shares",
    "summary": "Dow's 270-point rally highlighted by gains in UnitedHealth, Nike shares",
    "url": "https://finnhub.io/api/news?id=aa0c23ed91536c679fc9e2095e6ce9eba908f0388919a11fa5094a7e34b7cc3d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764761640,
      "headline": "Dow's 270-point rally highlighted by gains in UnitedHealth, Nike shares",
      "id": 137682275,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow's 270-point rally highlighted by gains in UnitedHealth, Nike shares",
      "url": "https://finnhub.io/api/news?id=aa0c23ed91536c679fc9e2095e6ce9eba908f0388919a11fa5094a7e34b7cc3d"
    }
  },
  {
    "ts": null,
    "headline": "Janux Therapeutics: Downgrading To \"Hold\" Rating After Latest Updated Phase 1 JANX007 mCRPC Data",
    "summary": "Janux Therapeutics (JANX) stock is downgraded to Hold after trial setbacks. Read what this means for investors and key upcoming catalysts.",
    "url": "https://finnhub.io/api/news?id=b7fdceddfb70bd2e34b59cd7e9bd0b3d50ebdcaa5e285f8f65e6ded6887f9fc0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764757327,
      "headline": "Janux Therapeutics: Downgrading To \"Hold\" Rating After Latest Updated Phase 1 JANX007 mCRPC Data",
      "id": 137670802,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2240114022/image_2240114022.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Janux Therapeutics (JANX) stock is downgraded to Hold after trial setbacks. Read what this means for investors and key upcoming catalysts.",
      "url": "https://finnhub.io/api/news?id=b7fdceddfb70bd2e34b59cd7e9bd0b3d50ebdcaa5e285f8f65e6ded6887f9fc0"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Maintains Price Target on Amgen (AMGN) Before Key Trial Readouts",
    "summary": "Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 price target and Buy rating for Amgen Inc. (NASDAQ:AMGN) on November 25 ahead of two Phase 2 updates for the company’s obesity medication MariTide, which are anticipated by year’s end. Following previously disclosed induction results from Part […]",
    "url": "https://finnhub.io/api/news?id=3071d5bb2c43093feb052c2669b24bf97ac3848e52b460d5867a0702ade5d426",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764745065,
      "headline": "Goldman Sachs Maintains Price Target on Amgen (AMGN) Before Key Trial Readouts",
      "id": 137667801,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 price target and Buy rating for Amgen Inc. (NASDAQ:AMGN) on November 25 ahead of two Phase 2 updates for the company’s obesity medication MariTide, which are anticipated by year’s end. Following previously disclosed induction results from Part […]",
      "url": "https://finnhub.io/api/news?id=3071d5bb2c43093feb052c2669b24bf97ac3848e52b460d5867a0702ade5d426"
    }
  }
]